4552 — JCR Pharmaceuticals Co Cashflow Statement
0.000.00%
- ¥67bn
- ¥93bn
- ¥33bn
- 19
- 37
- 56
- 27
Annual cashflow statement for JCR Pharmaceuticals Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 8,653 | 19,404 | 5,412 | 7,244 | -6,414 |
Depreciation | |||||
Non-Cash Items | 47 | -306 | -733 | 416 | 239 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -252 | -11,754 | -12,175 | -1,545 | -2,684 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 10,340 | 9,289 | -5,499 | 9,312 | -5,485 |
Capital Expenditures | -7,527 | -11,333 | -8,560 | -2,095 | -9,888 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 4,237 | 8,083 | -6,442 | -595 | 14 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -3,290 | -3,250 | -15,002 | -2,690 | -9,874 |
Financing Cash Flow Items | 1 | — | -1 | -46 | -55 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 8,304 | -2,179 | 1,948 | -2,031 | 9,736 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 15,332 | 4,472 | -17,454 | 5,477 | -5,559 |